RE:RE:RE:RE:RE:RE:New Press Release - Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study A new investor like us longs should think, that this MC is way too low given our accomplishments. Compared to peers such as CGON, $2.6 Billion US, IBRX, $ 2 Billion US, we could go up 50-100 times to catch up in MC value. Short term catalysts are BTD, more data, Licensing agreements with Big Pharma. More preclinical data on GBM or NSCLC for XPDT which in of itself is a potential wirth of many Billions. At $30 million MC vs $2-3 Billion one could think and hope that once BTD is granted, everyone will take TLT seriously. All IMHO
beenthere wrote: That's great but it's coming from an investor who has been here for years and knows much about TLT.
What would you think what a new investor who would know very little about TLT think after reading this news? Would they be interested and dig deeper or think 3 years in the making .. maybe. I think I will pass! At best I might add it to my watch list.